JP2024112834A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024112834A5 JP2024112834A5 JP2024075968A JP2024075968A JP2024112834A5 JP 2024112834 A5 JP2024112834 A5 JP 2024112834A5 JP 2024075968 A JP2024075968 A JP 2024075968A JP 2024075968 A JP2024075968 A JP 2024075968A JP 2024112834 A5 JP2024112834 A5 JP 2024112834A5
- Authority
- JP
- Japan
- Prior art keywords
- antisense oligonucleotide
- linkage
- sarm1
- seq
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962940437P | 2019-11-26 | 2019-11-26 | |
| US62/940,437 | 2019-11-26 | ||
| JP2022530807A JP7528212B2 (ja) | 2019-11-26 | 2020-11-25 | 神経保護のための方法および組成物 |
| PCT/US2020/062289 WO2021108602A1 (en) | 2019-11-26 | 2020-11-25 | Methods and compositions for neuroprotection |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022530807A Division JP7528212B2 (ja) | 2019-11-26 | 2020-11-25 | 神経保護のための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024112834A JP2024112834A (ja) | 2024-08-21 |
| JP2024112834A5 true JP2024112834A5 (https=) | 2024-11-11 |
| JP7796797B2 JP7796797B2 (ja) | 2026-01-09 |
Family
ID=74046136
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022530807A Active JP7528212B2 (ja) | 2019-11-26 | 2020-11-25 | 神経保護のための方法および組成物 |
| JP2024075968A Active JP7796797B2 (ja) | 2019-11-26 | 2024-05-08 | 神経保護のための方法および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022530807A Active JP7528212B2 (ja) | 2019-11-26 | 2020-11-25 | 神経保護のための方法および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12595481B2 (https=) |
| EP (1) | EP4065714A1 (https=) |
| JP (2) | JP7528212B2 (https=) |
| KR (1) | KR20220119366A (https=) |
| CN (1) | CN115176002A (https=) |
| AU (1) | AU2020391206A1 (https=) |
| BR (1) | BR112022009772A2 (https=) |
| IL (1) | IL293123A (https=) |
| MX (1) | MX2022006146A (https=) |
| TW (1) | TW202134436A (https=) |
| WO (1) | WO2021108602A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4065714A1 (en) * | 2019-11-26 | 2022-10-05 | Disarm Therapeutics, Inc. | Methods and compositions for neuroprotection |
| PE20242222A1 (es) * | 2022-03-14 | 2024-11-19 | Lilly Co Eli | Agentes de interferencia de arn de sarm1 |
| CN116059367B (zh) * | 2022-07-15 | 2025-02-18 | 浙江乘时佳生物科技有限公司 | 一种治疗阿尔茨海默症的sarm1抑制剂 |
| JP2025523905A (ja) * | 2022-07-21 | 2025-07-25 | アミリックス ファーマシューティカルズ，インコーポレイティッド | オリゴヌクレオチド組成物及びその方法 |
| TW202547525A (zh) | 2024-02-02 | 2025-12-16 | 美商美國禮來大藥廠 | SARM1 RNAi藥劑 |
| GB202408068D0 (en) | 2024-06-06 | 2024-07-24 | Univ London | Treatment of cancer of the central nervous system |
| WO2025261431A1 (zh) * | 2024-06-19 | 2025-12-26 | 上海拓界生物医药科技有限公司 | 靶向SARM1的RNAi剂及其医药用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040096830A1 (en) | 2002-11-16 | 2004-05-20 | Isis Pharmaceuticals Inc. | Modulation of protein kinase D2 expression |
| US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| US20050244851A1 (en) * | 2004-01-13 | 2005-11-03 | Affymetrix, Inc. | Methods of analysis of alternative splicing in human |
| CA2566519C (en) * | 2004-05-14 | 2020-04-21 | Rosetta Genomics Ltd. | Micrornas and uses thereof |
| US7901882B2 (en) * | 2006-03-31 | 2011-03-08 | Affymetrix, Inc. | Analysis of methylation using nucleic acid arrays |
| JP2013003911A (ja) * | 2011-06-17 | 2013-01-07 | Sony Corp | 電子機器、電子機器の制御方法およびプログラム |
| US20120328629A1 (en) | 2011-06-24 | 2012-12-27 | University Of Miami | Therapeutic Applications Targeting SARM1 |
| EP3294342A4 (en) | 2015-05-08 | 2018-11-07 | President and Fellows of Harvard College | Universal donor stem cells and related methods |
| JP7198489B2 (ja) * | 2016-03-23 | 2023-01-04 | 国立大学法人 岡山大学 | リン酸化ｓａｒｍ１、抗体、ｓａｒｍ１リン酸化阻害剤、神経変性疾患の予防又は治療薬、スクリーニング方法、ｓａｒｍ１改変体及び使用 |
| AU2017292173B2 (en) | 2016-07-06 | 2022-01-13 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of pain related disorders |
| WO2018057989A1 (en) | 2016-09-24 | 2018-03-29 | Washington University | INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF |
| EP3585897A1 (en) * | 2017-02-22 | 2020-01-01 | CRISPR Therapeutics AG | Materials and methods for treatment of dystrophic epidermolysis bullosa (deb) and other collagen type vii alpha 1 chain (col7a1) gene related conditions or disorders |
| US12576130B2 (en) * | 2017-10-18 | 2026-03-17 | Washington University | Dominant negative SARM1 molecules comprising a substitution at position 189, 190, 193, 194, 570 and/or 685 of SARM1 |
| US12448374B2 (en) * | 2018-06-07 | 2025-10-21 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| JP7481329B2 (ja) | 2018-06-07 | 2024-05-10 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１阻害剤 |
| ES3028093T3 (en) | 2018-06-07 | 2025-06-18 | Disarm Therapeutics Inc | Inhibitors of sarm1 |
| EP4065714A1 (en) * | 2019-11-26 | 2022-10-05 | Disarm Therapeutics, Inc. | Methods and compositions for neuroprotection |
-
2020
- 2020-11-25 EP EP20829411.6A patent/EP4065714A1/en active Pending
- 2020-11-25 BR BR112022009772A patent/BR112022009772A2/pt not_active IP Right Cessation
- 2020-11-25 JP JP2022530807A patent/JP7528212B2/ja active Active
- 2020-11-25 AU AU2020391206A patent/AU2020391206A1/en not_active Abandoned
- 2020-11-25 IL IL293123A patent/IL293123A/en unknown
- 2020-11-25 MX MX2022006146A patent/MX2022006146A/es unknown
- 2020-11-25 CN CN202080082124.2A patent/CN115176002A/zh active Pending
- 2020-11-25 TW TW109141403A patent/TW202134436A/zh unknown
- 2020-11-25 US US17/778,567 patent/US12595481B2/en active Active
- 2020-11-25 WO PCT/US2020/062289 patent/WO2021108602A1/en not_active Ceased
- 2020-11-25 KR KR1020227017020A patent/KR20220119366A/ko not_active Withdrawn
-
2024
- 2024-05-08 JP JP2024075968A patent/JP7796797B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024112834A5 (https=) | ||
| US11920132B2 (en) | Oligonucleotide therapy for Leber congenital amaurosis | |
| US5194428A (en) | Inhibition of influenza virus replication by oligonucleotide phosphorothioates | |
| US6372427B1 (en) | Cooperative oligonucleotides | |
| CN115697420A (zh) | 一种治疗赫勒氏综合征的方法和药物 | |
| JPWO2022270585A5 (https=) | ||
| CN115516092A (zh) | 血管生成素样3(ANGPTL3)的siRNA及其用途 | |
| CA2457528A1 (en) | Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina) | |
| JPH08510900A (ja) | 改良された抗インフルエンザ活性を有する修飾オリゴヌクレオチド | |
| US5637573A (en) | Influenza virus replication inhibiting oligonucleotide analogues and their pharmaceutical compositions | |
| JP2024073525A5 (https=) | ||
| US5650502A (en) | Ribozyme analogs having rigid non-nucleotidic linkers | |
| WO2017186815A1 (en) | Antisense oligonucleotides for enhanced expression of frataxin | |
| JP2021513851A5 (https=) | ||
| JPWO2020227758A5 (https=) | ||
| WO1997038097A1 (en) | Cooperative oligonucleotides | |
| RU2024106447A (ru) | Антисмысловые олигонуклеотиды, нацеленные на ген cav3.1, и их применения | |
| AU2003236659B2 (en) | Cooperative oligonucleotides | |
| JPWO2020255007A5 (https=) | ||
| AU2003236659A1 (en) | Cooperative oligonucleotides | |
| JPWO2022061108A5 (https=) | ||
| WO2024077262A2 (en) | Methods and compositions for silencing elavl2 expression for the treatment of disease | |
| JPWO2022271699A5 (https=) | ||
| JPWO2019161105A5 (https=) | ||
| JPWO2023288240A5 (https=) |